Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaniaga BhdXKLS:7081 46 EBIT per Share is RM0.18 as of Mar. 2026. GuruFocus rates XKLS:7081 with a GF Score™ of 46/100 and a GF Value™ of RM0.69 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 105 Medical Distribution companies, Pharmaniaga Bhd ranks worse than 952380% on this metric.
Pharmaniaga Bhd's EBIT per Share for the
three
months ended in Mar. 2026 was RM0.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was RM0.18.
During the past 12 months, the average EBIT per Share Growth Rate of Pharmaniaga Bhd was -70.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Pharmaniaga Bhd's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Pharmaniaga Bhd was 43.00% per year. The lowest was -50.50% per year. And the median was -1.90% per year.
XKLS:7081's 3-Year EBIT Growth Rate is not ranked *
in the Medical Distribution industry.
Industry Median: 4 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Pharmaniaga Bhd's EBIT for the
three
months ended in Mar. 2026 was RM56 Mil.
Pharmaniaga Bhd (XKLS:7081) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Pharmaniaga Bhd EBIT per Share Related Terms
Pharmaniaga Bhd EBIT per Share Historical Data
* Premium members only.
The historical data trend for Pharmaniaga Bhd's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaniaga Bhd (XKLS:7081) has a EBIT per Share of RM0.18 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharmaniaga Bhd and its competitors. According to the industry distribution chart, Pharmaniaga Bhd ranks #999999 out of 105 companies in the Medical Distribution industry.
Is Pharmaniaga Bhd's EBIT per Share too high?
Pharmaniaga Bhd's current EBIT per Share is RM0.18. Based on the distribution chart, Pharmaniaga Bhd ranks #999999 out of 105 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Pharmaniaga Bhd has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's EBIT per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Pharmaniaga Bhd ranks #999999 out of 105 companies for EBIT per Share. This places Pharmaniaga Bhd in the lower half of its industry. The industry median EBIT per Share is 4.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.00, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharmaniaga Bhd and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaniaga Bhd's current EBIT per Share is RM0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.69, compared to a current price of RM1.17 — trading 69.6% above its estimated fair value. The current EBIT per Share is RM0.18. Pharmaniaga Bhd's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current EBIT per Share is RM0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued.
The current stock price of RM1.17 is trading 69.6% above its estimated GF Value™ of RM0.69.
GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.
Key valuation signals for XKLS:7081:
EBIT per Share: RM0.18
GF Value™: RM0.69 vs. price of RM1.17 (69.6% above fair value)
No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
46GF Score
Get the complete analysis for XKLS:7081
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7081 has been successfully added to your 
